Joel D. Mermis
Expertise in
5
conditions

Dr. Joel D. Mermis

Pulmonary Medicine
2000 Olathe Boulevard, 
Kansas City, KS 
On Staff At
Accepting New Patients
Offers Telehealth
23 Years of Experience
Referral may be required
Expertise in
5
conditions
2000 Olathe Boulevard, 
Kansas City, KS 

Overview

Joel Mermis is a Pulmonary Medicine provider practicing medicine in Kansas City, Kansas. He has been practicing medicine for over 23 years.

Dr. Mermis is highly rated in 5 conditions, according to our data. His clinical expertise encompasses Cystic Fibrosis, Secondary Immunodeficiency (SID), Newborn Jaundice, Bronchiectasis, and Thyroidectomy.

Dr. Mermis is board certified in American Board Of Internal Medicine, Critical Care Medicine - 2010 and American Board Of Internal Medicine, Pulmonary Disease - 2009. He is actively involved in clinical research, co-authoring 17 peer reviewed articles and participating in 4 clinical trials. Dr. Mermis is currently accepting new patients.

Graduate Institution

University Of Kansas School Of Medicine, Doctor Of Medicine, 2003

Residency

Emory University School of Medicine, Internal Medicine, 2007

Specialties

Pulmonary Medicine

Licenses

Internal Medicine in KS

Board Certifications

American Board Of Internal Medicine, Critical Care Medicine - 2010
American Board Of Internal Medicine, Pulmonary Disease - 2009

Fellowships

University of Kansas Medical Center, Pulmonary Medicine and Critical Care Medicine, 2010

Hospital Affiliations

University Of Kansas Hospital

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cambia Health Solutions
  • EPO
  • INSURANCE PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • PPO
Change Healthcare
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Cigna
  • EPO
  • HMO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Home State Health
  • EPO
Horizon Healthcare
  • EPO
  • POS
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
Oscar
  • EPO
  • HMO
  • PPO
Sunflower Health Plan
  • HMO
  • MANAGED MEDICAID PLAN
TeamCare
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 14 Less Insurance Carriers -

Locations

Medical Pavilion
2000 Olathe Boulevard, Kansas City, KS 66160
Other Locations
The University of Kansas Hospital
4000 Cambridge Street, Kansas City, KS 66160

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

4 Clinical Trials

A Phase III, Randomized, Double-blind, Placebo-controlled Study of AeroVanc for the Treatment of Persistent Methicillin-resistant Staphylococcus Aureus Lung Infection in Cystic Fibrosis Patients
A Phase III, Randomized, Double-blind, Placebo-controlled Study of AeroVanc for the Treatment of Persistent Methicillin-resistant Staphylococcus Aureus Lung Infection in Cystic Fibrosis Patients
Enrollment Status: Completed
Publish Date: December 16, 2022
Intervention Type: Drug
Study Phase: Phase 3
A Phase 1b Randomized, Double-blind, Placebo-Controlled Trial to Evaluate the Safety of CB-280 in Patients With Cystic Fibrosis
A Phase 1b Randomized, Double-blind, Placebo-Controlled Trial to Evaluate the Safety of CB-280 in Patients With Cystic Fibrosis
Enrollment Status: Completed
Publish Date: April 13, 2022
Intervention Type: Drug
Study Drug: CB-280 Arginase Inhibitor
Study Phase: Phase 1
A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy, Safety, and Tolerability of CTX-4430 Administered Orally Once-Daily for 48 Weeks in Adult Patients With Cystic Fibrosis
A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy, Safety, and Tolerability of CTX-4430 Administered Orally Once-Daily for 48 Weeks in Adult Patients With Cystic Fibrosis
Enrollment Status: Completed
Publish Date: September 04, 2019
Intervention Type: Drug
Study Phase: Phase 2
Phase 1b, Randomized, Double-blind, Placebo-controlled, Dose Escalation Study to Evaluate the Safety, Tolerability and Pharmacokinetics of QR-010 in Subjects With Homozygous ΔF508 Cystic Fibrosis
Phase 1b, Randomized, Double-blind, Placebo-controlled, Dose Escalation Study to Evaluate the Safety, Tolerability and Pharmacokinetics of QR-010 in Subjects With Homozygous ΔF508 Cystic Fibrosis
Enrollment Status: Completed
Publish Date: February 06, 2019
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
View 3 Less Clinical Trials

17 Total Publications

Vanzacaftor-tezacaftor-deutivacaftor versus elexacaftor-tezacaftor-ivacaftor in individuals with cystic fibrosis aged 12 years and older (SKYLINE Trials VX20-121-102 and VX20-121-103): results from two randomised, active-controlled, phase 3 trials.
Vanzacaftor-tezacaftor-deutivacaftor versus elexacaftor-tezacaftor-ivacaftor in individuals with cystic fibrosis aged 12 years and older (SKYLINE Trials VX20-121-102 and VX20-121-103): results from two randomised, active-controlled, phase 3 trials.
Journal: The Lancet. Respiratory medicine
Published: October 25, 2024
Similar Doctors
Expertise in
8
conditions
Dr. Scott M. Matson
Pulmonary Medicine
Expertise in
8
conditions
Dr. Scott M. Matson
Pulmonary Medicine

Medical Pavilion

2000 Olathe Boulevard, 
Kansas City, KS 
 (0.3 miles away)
913-588-1227
Experience:
13+ years
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Scott Matson is a Pulmonary Medicine provider practicing medicine in Kansas City, Kansas. He has been practicing medicine for over 13 years. Dr. Matson is highly rated in 8 conditions, according to our data. His clinical expertise encompasses Interstitial Lung Disease, Acute Interstitial Pneumonia, Rheumatoid Lung Disease, and Pulmonary Fibrosis. Dr. Matson is board certified in American Board Of Internal Medicine, Critical Care Medicine - 2020 , American Board Of Internal Medicine, Pulmonary Disease - 2019 , and American Board Of Internal Medicine, Internal Medicine - 2016. Dr. Matson is currently accepting new patients.

Expertise in
17
conditions
Dr. Mark J. Hamblin
Pulmonary Medicine
Expertise in
17
conditions
Dr. Mark J. Hamblin
Pulmonary Medicine

College Square Medical Pavilion

12000 West 110th Street, 
Overland Park, KS 
 (10.8 miles away)
913-588-1227
Experience:
23+ years
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Mark Hamblin is a Pulmonary Medicine provider practicing medicine in Overland Park, Kansas. He has been practicing medicine for over 23 years. Dr. Hamblin is highly rated in 17 conditions, according to our data. His clinical expertise encompasses Interstitial Lung Disease, Acute Interstitial Pneumonia, Pulmonary Fibrosis, Sarcoidosis, and Bone Marrow Aspiration. Dr. Hamblin is board certified in American Board Of Internal Medicine, Critical Care Medicine - 2012 and American Board Of Internal Medicine, Pulmonary Disease - 2011. Dr. Hamblin is currently accepting new patients.

Expertise in
7
conditions
Dr. Leslie A. Spikes
Pulmonary Medicine
Expertise in
7
conditions
Dr. Leslie A. Spikes
Pulmonary Medicine

Medical Pavilion

2000 Olathe Boulevard, 
Kansas City, KS 
 (0.3 miles away)
913-588-1227
Experience:
22+ years
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Leslie Spikes is a Pulmonary Medicine provider practicing medicine in Kansas City, Kansas. She has been practicing medicine for over 22 years. Dr. Spikes is highly rated in 7 conditions, according to our data. Her clinical expertise encompasses Pulmonary Hypertension, Pulmonary Veno-Occlusive Disease, Acute Interstitial Pneumonia, Lung Metastases, and Endoscopy. Dr. Spikes is board certified in American Board Of Internal Medicine, Critical Care Medicine - 2010 and American Board Of Internal Medicine, Pulmonary Disease - 2009. Dr. Spikes is currently accepting new patients.

Frequently Asked Questions about Dr. Joel D. Mermis

How do I make an appointment with Dr. Joel D. Mermis?

You can book an appointment with Dr. Joel D. Mermis by calling their office at 913-588-1227. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Joel D. Mermis a top-rated expert for Cystic Fibrosis?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Joel D. Mermis is classified as an Elite expert for Cystic Fibrosis, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Joel D. Mermis specialize in?

While Dr. Joel D. Mermis is a Pulmonary Medicine, they have specific expertise in Cystic Fibrosis, Secondary Immunodeficiency (SID), and Newborn Jaundice. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Pulmonary Medicine.

Does Dr. Joel D. Mermis participate in research or clinical trials?

Yes. Dr. Joel D. Mermis has published 17 articles and abstracts on conditions like Cystic Fibrosis. You can view a list of Dr. Joel D. Mermis's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Joel D. Mermis accept my insurance?

Dr. Joel D. Mermis accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 913-588-1227 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Mermis's expertise for a condition
ConditionClose
View All 19 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile